Janssen starts a new clinical trial as manufacturing issue is addressed
Janssen, a multinational pharmaceutical company owning the license of JNJ-64565111, a Hanmi Pharm’s biologic for the treatment of diabetes and obesity, will start a new clinical trial at the end of this year as the ‘manufacturing delay’ issue was addressed.
Hanmi Pharm(CEO Sae-Chang Kwon, Jong-S...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.